Your browser doesn't support javascript.
loading
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?
Miglietta, F; Dieci, M V; Griguolo, G; Guarneri, V; Conte, P F.
Afiliação
  • Miglietta F; Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Dieci MV; Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic address: mariavittoria.dieci@unipd.it.
  • Griguolo G; Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Guarneri V; Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Conte PF; Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Cancer Treat Rev ; 60: 100-108, 2017 Nov.
Article em En | MEDLINE | ID: mdl-28942029

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Algoritmos / Neoplasias da Mama / Receptor ErbB-2 / Terapia de Alvo Molecular / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Algoritmos / Neoplasias da Mama / Receptor ErbB-2 / Terapia de Alvo Molecular / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article